Dh9, A Novel Ppar Gamma Agonist Suppresses The Proliferation Of Adpkd Epithelial Cells: An Association With An Inhibition Of Beta-Catenin Signaling
INVESTIGATIONAL NEW DRUGS(2010)
摘要
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that exclusively progresses to renal failure. An important target for the treatment of ADPKD is to reduce cystic cell proliferation. PPAR gamma agonists such as TZDs are insulin sensitizing agents that have also been reported to decrease tumor growth. Here we tested DH9, a newly synthesized PPAR gamma agonist on the proliferation of an ADPKD cell line, WT9-12. DH9 showed a potent anti-proliferative activity against ADPKD cells. At high concentration, DH9 also induced apoptotic cell death. The effect of DH9 on cell proliferation was mediated by a PPAR gamma independent mechanism. Since DH9 decreased the levels of beta-catenin in cells via a GSK3 beta mediated degradation pathway, this acts as a mechanism for growth inhibition by DH9.
更多查看译文
关键词
ADPKD,PPAR gamma,alpha-aryloxy-alpha-methylhydrocinnamic acid derivative,beta-catenin,GSK3 beta
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要